Modeling of the impact of biological drugs in the economic burden of severe asthma
Bronchial asthma (BA) is worldwide lungs’ illness, at least 1,5 mln people are on a dispensary in Russia. Non-control severe BA (SBA) can lead to increasing of direct Health Care System expenditures due to very oft en exacerbations (drugs costs, hospitalizations and out-patient cure etc.) as well as...
Main Authors: | S. K. Zyryanov, I. N. Dyakov, O. I. Karpov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2020-01-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/462 |
Similar Items
-
Dupilumab in the treatment of severe non-control broncial asthma — economic aspects
by: A. S. Salasyuk, et al.
Published: (2019-10-01) -
Severe bronchial asthma patient care organization in various regions of the Russian Federation. From endotypes and phenotypes of bronchial asthma to personalized choice of therapy
by: S. N. Avdeev, et al.
Published: (2020-02-01) -
Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study
by: Numata T, et al.
Published: (2021-06-01) -
Experience of using dupilumab in the treatment of severe asthma
by: G. L. Ignatova, et al.
Published: (2020-09-01) -
Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction
by: Ramphul M, et al.
Published: (2021-05-01)